吡咯替尼治疗HER-2阳性晚期乳腺癌患者的近期疗效观察

Short-Term Efficacy of Pyrotinib in the Treatment of Advanced HER-2 Positive Breast Cancer

目的探讨吡咯替尼治疗HER-2阳性晚期乳腺癌患者的近期临床疗效和安全性。方法回顾性分析2019年3月—2020年1月我院收治的采用吡咯替尼治疗既往曲妥珠单抗治疗失败的HER-2阳性晚期乳腺癌患者,评价近期临床疗效和不良反应。结果22例患者中,部分缓解15例,疾病稳定4例,疾病进展3例,ORR为68.18%(15/22),DCR为86.38%(19/22)。使用吡咯替尼期间发生的不良反应以粒细胞减少、腹泻最为常见,Ⅲ-Ⅳ级粒细胞减少的发生率为22.73%(5/22)、腹泻的发生率为9.09%(2/22),总体耐受良好。结论吡咯替尼对既往曲妥珠单抗治疗失败的HER-2阳性晚期乳腺癌患者的近期疗效较理想,安全性较好。

Objective To investigate the short-term clinical efficacy and safety of pyrotinib in the treatment of advanced HER-2 positive breast cancer.Methods A retrospective analysis of 22 patients with HER-2 positive breast cancer in our hospital between March 2019 and January 2020 was performed.All patients had failed from previous trastuzumab treatment,and they were then treated with pyrotinib.The shortterm clinical efficacy and side effects were evaluated.Results Of the 22 patients,15 cases were evaluated as partial remission,four cases as stable,three cases as disease progression.The overall objective remission rate(ORR)was 68.18%(15/22),and the disease control rate(DCR)was 86.38%(19/22).The most common adverse reactions were granulocytopenia and diarrhea,and the incidence of gradeⅢ-Ⅳgranulocytopenia was 22.73%(5/22)and of diarrhea was 9.09%(2/22).Patients showed a good overall tolerance.Conclusion Pyrotinib showed satisfactory shortterm efficacy and good safety for patients with advanced HER-2 positive breast cancer who had previously failed trastuzumab therapy.